OssiFi is developing best in class sclerostin small molecule inhibitors to take advantage of new opportunities to develop safer, more effective bone building therapies.
OssiFi Therapeutics is an innovative bone-biology company operating at the intersection of therapeutics and medical devices to address significant unmet needs in neurogenic low back pain, fracture repair, and fracture prevention.